In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance

Kimiko Ubukata, Satoshi Iwata, Keisuke Sunakawa

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The comparative in vitro activity of a new ketolide, telithromycin (TEL), and eight other macrolide-lincosamide antibiotics (MLS) against 215 strains, of Streptococcus pneumoniae including penicillin-resistant isolates (PRSP), was determined by the agar dilution method. These strains were isolated from patients with pneumonia, otitis media, and purulent meningitis between 1995 and 1997. Two genes, mefA and ermB, that encode MLS resistance in the strains were identified by polymerase chain reaction (PCR). Of the strains, 30.2% (n = 65) had the mefA gene, 37.7% (n = 81) had the ermB gene, and 1.4% (n = 3) had both resistant genes. The minimum inhibitory concentration (MIC90s) of TEL and 16-membered ring MLS for strains having the mefA gene were 0.063-0.25 μg/ml, which were the same level as those for MLS-susceptible strains. On the other hand, the strains with the mefA gene showed low-level resistance to 14- and 15-membered ring MLS, with MIC90s ranging from 1 to 4 μg/ml. Only the MIC90 of TEL at 0.5 μg/ml, for strains having the ermB gene was superior to that of the 14-, 15-, and 16-membered ring MLS (MIC90, ≥ 64 μg/ml). TEL also showed excellent activity against PRSP having abnormal pbp1a, pbp2x, and pbp2b genes. Most strains having the mefA and ermB genes were serotyped to 3, 6, 14, 19, and 23. These results suggest that TEL may be a useful chemotherapeutic agent for respiratory tract infections caused by S. pneumoniae.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume9
Issue number3
DOIs
Publication statusPublished - 2003 Sep
Externally publishedYes

Fingerprint

Ketolides
Macrolides
Streptococcus pneumoniae
Lincosamides
Anti-Bacterial Agents
Genes
Suppurative Otitis Media
In Vitro Techniques
telithromycin
Microbial Sensitivity Tests
Microbial Drug Resistance
Meningitis
Respiratory Tract Infections
Penicillins
Agar
Pneumonia

Keywords

  • ErmB gene
  • Macrolide antibiotic resistance
  • mefA gene
  • Streptococcus pneumoniae
  • Telithromycin

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance. / Ubukata, Kimiko; Iwata, Satoshi; Sunakawa, Keisuke.

In: Journal of Infection and Chemotherapy, Vol. 9, No. 3, 09.2003, p. 221-226.

Research output: Contribution to journalArticle

@article{739b9092b8bc4aa4a6dca7e49ef5fd9a,
title = "In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance",
abstract = "The comparative in vitro activity of a new ketolide, telithromycin (TEL), and eight other macrolide-lincosamide antibiotics (MLS) against 215 strains, of Streptococcus pneumoniae including penicillin-resistant isolates (PRSP), was determined by the agar dilution method. These strains were isolated from patients with pneumonia, otitis media, and purulent meningitis between 1995 and 1997. Two genes, mefA and ermB, that encode MLS resistance in the strains were identified by polymerase chain reaction (PCR). Of the strains, 30.2{\%} (n = 65) had the mefA gene, 37.7{\%} (n = 81) had the ermB gene, and 1.4{\%} (n = 3) had both resistant genes. The minimum inhibitory concentration (MIC90s) of TEL and 16-membered ring MLS for strains having the mefA gene were 0.063-0.25 μg/ml, which were the same level as those for MLS-susceptible strains. On the other hand, the strains with the mefA gene showed low-level resistance to 14- and 15-membered ring MLS, with MIC90s ranging from 1 to 4 μg/ml. Only the MIC90 of TEL at 0.5 μg/ml, for strains having the ermB gene was superior to that of the 14-, 15-, and 16-membered ring MLS (MIC90, ≥ 64 μg/ml). TEL also showed excellent activity against PRSP having abnormal pbp1a, pbp2x, and pbp2b genes. Most strains having the mefA and ermB genes were serotyped to 3, 6, 14, 19, and 23. These results suggest that TEL may be a useful chemotherapeutic agent for respiratory tract infections caused by S. pneumoniae.",
keywords = "ErmB gene, Macrolide antibiotic resistance, mefA gene, Streptococcus pneumoniae, Telithromycin",
author = "Kimiko Ubukata and Satoshi Iwata and Keisuke Sunakawa",
year = "2003",
month = "9",
doi = "10.1007/s10156-003-0258-2",
language = "English",
volume = "9",
pages = "221--226",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance

AU - Ubukata, Kimiko

AU - Iwata, Satoshi

AU - Sunakawa, Keisuke

PY - 2003/9

Y1 - 2003/9

N2 - The comparative in vitro activity of a new ketolide, telithromycin (TEL), and eight other macrolide-lincosamide antibiotics (MLS) against 215 strains, of Streptococcus pneumoniae including penicillin-resistant isolates (PRSP), was determined by the agar dilution method. These strains were isolated from patients with pneumonia, otitis media, and purulent meningitis between 1995 and 1997. Two genes, mefA and ermB, that encode MLS resistance in the strains were identified by polymerase chain reaction (PCR). Of the strains, 30.2% (n = 65) had the mefA gene, 37.7% (n = 81) had the ermB gene, and 1.4% (n = 3) had both resistant genes. The minimum inhibitory concentration (MIC90s) of TEL and 16-membered ring MLS for strains having the mefA gene were 0.063-0.25 μg/ml, which were the same level as those for MLS-susceptible strains. On the other hand, the strains with the mefA gene showed low-level resistance to 14- and 15-membered ring MLS, with MIC90s ranging from 1 to 4 μg/ml. Only the MIC90 of TEL at 0.5 μg/ml, for strains having the ermB gene was superior to that of the 14-, 15-, and 16-membered ring MLS (MIC90, ≥ 64 μg/ml). TEL also showed excellent activity against PRSP having abnormal pbp1a, pbp2x, and pbp2b genes. Most strains having the mefA and ermB genes were serotyped to 3, 6, 14, 19, and 23. These results suggest that TEL may be a useful chemotherapeutic agent for respiratory tract infections caused by S. pneumoniae.

AB - The comparative in vitro activity of a new ketolide, telithromycin (TEL), and eight other macrolide-lincosamide antibiotics (MLS) against 215 strains, of Streptococcus pneumoniae including penicillin-resistant isolates (PRSP), was determined by the agar dilution method. These strains were isolated from patients with pneumonia, otitis media, and purulent meningitis between 1995 and 1997. Two genes, mefA and ermB, that encode MLS resistance in the strains were identified by polymerase chain reaction (PCR). Of the strains, 30.2% (n = 65) had the mefA gene, 37.7% (n = 81) had the ermB gene, and 1.4% (n = 3) had both resistant genes. The minimum inhibitory concentration (MIC90s) of TEL and 16-membered ring MLS for strains having the mefA gene were 0.063-0.25 μg/ml, which were the same level as those for MLS-susceptible strains. On the other hand, the strains with the mefA gene showed low-level resistance to 14- and 15-membered ring MLS, with MIC90s ranging from 1 to 4 μg/ml. Only the MIC90 of TEL at 0.5 μg/ml, for strains having the ermB gene was superior to that of the 14-, 15-, and 16-membered ring MLS (MIC90, ≥ 64 μg/ml). TEL also showed excellent activity against PRSP having abnormal pbp1a, pbp2x, and pbp2b genes. Most strains having the mefA and ermB genes were serotyped to 3, 6, 14, 19, and 23. These results suggest that TEL may be a useful chemotherapeutic agent for respiratory tract infections caused by S. pneumoniae.

KW - ErmB gene

KW - Macrolide antibiotic resistance

KW - mefA gene

KW - Streptococcus pneumoniae

KW - Telithromycin

UR - http://www.scopus.com/inward/record.url?scp=0142026531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142026531&partnerID=8YFLogxK

U2 - 10.1007/s10156-003-0258-2

DO - 10.1007/s10156-003-0258-2

M3 - Article

VL - 9

SP - 221

EP - 226

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -